Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L et al
Our peptides are prepared and compounded locally in Australia
This is not just a technical distinction
The Medicare GLP-1 Bridge program starts July 1, 2026, offering FDA-approved GLP-1 medications for weight loss at a $50 monthly copay for eligible Part D beneficiaries
Well, their blood pressure would go back up and we're not surprised
The increased gallstone risk may be attributable to two mechanisms: the rapid and substantial weight loss these medications facilitate, and potentially direct effects of GLP-1 agonists on reducing gallbladder motility and emptying